Health News Releases

  • Today May 18
November 23, 2018 10:25
Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer Immunotherapies World-Wide
Vineti, Inc., the leading digital “platform of record” for personalized therapies, today announced a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid
November 21, 2018 14:10
Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
November 21, 2018 13:40
ResMed Elects Harjit Gill to Its Board of Directors
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthca
November 20, 2018 13:45
Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan
Alvotech and Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar
November 16, 2018 17:25
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of mo
November 16, 2018 15:50
ResMed Completes Acquisition of MatrixCare
ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its $750 million acquis
November 16, 2018 10:25
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed
November 13, 2018 14:30
Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the Proposed Acquisition of Shire
Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited (“Takeda” or the “Company”) regarding the proposed acquisition (the “Acquisition”) of Shire plc (“Shire”), Takeda a
November 13, 2018 13:10
International Consensus Statement on Postoperative Anemia Management Recommends Noninvasive Hemoglobin Measurement Including Masimo SpHb®
Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blo
November 06, 2018 17:20
AlgaEnergy and Yokogawa Sign Strategic Partnership & Equity Agreement to Accelerate Growth of the Microalgae Biotech Sector
AlgaEnergy, a Spanish biotechnology company specializing in the production and commercial applications of microalgae, and Yokogawa Electric Corporation (TOKYO:6841), a leading provider of industrial a
November 06, 2018 13:40
ResMed to Acquire MatrixCare, Expands Out-of-Hospital SaaS Portfolio into Long-Term Care Settings
ResMed (NYSE: RMD) (ASX: RMD) today announced it has signed a definitive agreement to acquire privately held MatrixCare, a leader in U.S. long-term post-acute care software, serving more than 15,000 p
November 06, 2018 13:30
OptraSCAN® Unveils High-Speed, High-Throughput, High-Capacity and High-Content “Multi-Modality Digital Slide Scanner”
OptraSCAN®, the leading On-Demand Digital Pathology solution provider, today unveiled a new Multi-Modality Digital Slide Scanner, with features such as high-speed, high-throughput, high-capacity and h
November 06, 2018 10:35
Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial effectiveness results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed empagliflozin was associated with a 44 percent relative risk reduction in ho
November 06, 2018 09:00
Aurigene to Present Multiple Programs at the SITC 2018 in Washington D.C. and EORTC-NCI-AACR 2018 in Dublin
Aurigene: SITC - Nov 7-11, Washington D.C.: (a) CA-170 - Small molecule oral antagonist of PD-L1/VISTA in Ph-2 (India) (b) Small molecule oral antagonist of CD47 (c) Small molecule oral antago
November 05, 2018 10:30
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 18 company-sponsored abstracts at the 60th American Society of Hematology (ASH) Annual Meeting taking
November 01, 2018 14:20
Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatiti
November 01, 2018 14:15
Takeda Reports Second Quarter FY2018 Results
Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region · Underlying Revenue was solid at +4.2%, with continued strong mo
October 31, 2018 18:35
Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Pe
October 31, 2018 15:25
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer
Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced the clos
October 31, 2018 11:35
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1
The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and
October 29, 2018 13:25
Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of th
October 29, 2018 10:50
Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and Second Amendment to Bridge Credit Agreement in Connection with Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or “Takeda”) announces that it has today entered into a Senior Short Term Loan Facility Agreement (the “SSTL”) for an aggregate principal
October 26, 2018 15:40
Takeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of six company-sponsored abstracts, including two oral presentations, at the 11th International
October 25, 2018 17:15
Eminent Scientist James Till Turned Philanthropist; Donates Prize Money to the Cause of Young Researchers
Stem cell discoverer Prof. James Till, Professor Emeritus, University of Toronto, Canada who was awarded the Edogawa Niche Prize 2018 (www.edogawanicheprize.org), jointly by Nichi-In Centre for Regene
October 25, 2018 13:45
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting
25 per page50 per page75 per page100 per page